Eligibility criteriagraph


  • All cohorts must have prospective ovarian cancer outcomes
  • All cohorts must have basic epidemiologic data including oral contraceptive use and parity


  • Constitutional DNA (OCAC)
  • Blood
  • Serial blood (biomarker)
  • Histology data
  • Tissue

OC3 Cohorts

Adventist Health Study II (AHS2)

Black Women's  Health Study (BWHS)

Breakthrough Generations Study (BGS)  

Breast Cancer Detection Demonstration Project Follow-up Study (BCDDP)

California Teacher’s Study (CTS) 

Campaign against Cancer and Heart Disease (CLUE II) 

Canadian Study of Diet, Lifestyle, and Health (CSDLH)

Cancer Prevention Study II (CPSII)

European Prospective Investigation into Cancer Project (EPIC) 

Finnish Maternity Cohort (FMC)

Iowa Women's Health Study (IWHS)  

Melbourne Collaborative Cohort Study (MCCS) 

Multi-ethnic Cohort (MEC)

Netherlands Cohort Study (NLCS)

NIH-AARP Diet and Health Study (AARP)  

Northern Sweden Health and Disease Study (NSHDS)

Nurses’ Health Study (NHS)  

Nurses’ Health Study II (NHSII)  

NYU Women’s Health Study (NYUWHS) 

Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) 

Shanghai Women’s Health Study (SWHS) 

Singapore Chinese Health Study (SCHS)

Sister Study (SS)  

Southern Community Cohort Study (SCCS)

Swedish Mammography Cohort (SMC)

Vitamins and Lifestyle Study (VITAL)

Women’s Health Study (WHS)

Women’s Lifestyle and Health Study (WLH) 

Women’s Health Initiative (WHI) 



Grant  Ovarian Cancer Research Program (DoD)
Description Translational Leverage Award
Grant dates Sept. 29, 2012 - Sept. 28, 2015
Title Development of the Ovarian Cancer Cohort Consortium: Risk factor associations by heterogeneity of disease
Principal Investigator Shelley Tworoger